In our cohort, the improvement in WHO-FC, 6MWD, and NT-proBNP/BNP levels was somehow smaller in patients with than without a LHD phenotype, but survival was comparable, suggesting that a less aggressive therapy in PAH-LHD might be appropriate. This evidence concerns the gene NPPB and pulmonary arterial hypertension.